Clopidogrel

Generic Name: Clopidogrel

Brand Names: Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)

Drug Type: Small Molecule

Chemical Formula: C_₁₆H_₁₆ClNO_₂S

CAS Number: 113665-84-2

Unique Ingredient Identifier: A74586SNO7

Background: Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication: 1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions: Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events

Associated Therapies: -

Clinical Trials

Antiplatelet Therapy in HIV

Phase 2

Completed

Conditions: HIV
Cardiovascular Diseases
Inflammation

Interventions: Drug: Aspirin
Drug: Clopidogrel

First Posted Date: 2015-09-24

Last Posted Date: 2018-10-15

Lead Sponsor: NYU Langone Health

Target Recruit Count: 55

Registration Number: NCT02559414

Locations: 🇺🇸
Bellevue Hospital, New York, New York, United States
🇺🇸
NYU Langone Medical Center, New York, New York, United States

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Phase 3

Terminated

Conditions: Transcatheter Aortic Valve Replacement

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)
Drug: Acetylsalicylic Acid (ASA)
Drug: Clopidogrel
Drug: Vitamin K antagonist (VKA)

First Posted Date: 2015-09-22

Last Posted Date: 2020-01-13

Lead Sponsor: Bayer

Target Recruit Count: 1653

Registration Number: NCT02556203

Pharmacodynamic Study of Cilostazol in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Cilostazol
Drug: Acetylsalicylic acid
Drug: Clopidogrel

First Posted Date: 2015-09-18

Last Posted Date: 2021-10-13

Lead Sponsor: Otsuka Pharmaceutical Co., Ltd.

Target Recruit Count: 77

Registration Number: NCT02554721

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Phase 4

Completed

Conditions: Diabetes Mellitus
Myocardial Infarction
Peripheral Arterial Disease

Interventions: Drug: Vorapaxar
Drug: Clopidogrel
Drug: Aspirin

First Posted Date: 2015-09-14

Last Posted Date: 2020-02-12

Lead Sponsor: University of Florida

Target Recruit Count: 66

Registration Number: NCT02548650

Locations: 🇺🇸
University of Florida, Jacksonville, Florida, United States

Comparison of Loading Strategies With Antiplatelet Drugs in Patients Undergoing Elective Coronary Intervention

Phase 4

Terminated

Conditions: Angina Pectoris

Interventions: Drug: Prasugrel
Drug: Clopidogrel

First Posted Date: 2015-09-14

Last Posted Date: 2020-07-17

Lead Sponsor: LMU Klinikum

Target Recruit Count: 795

Registration Number: NCT02548611

Locations: 🇩🇪
Deutsches Herzzentrum Muenchen, Munich, Germany
🇩🇪
Munich University Hospital, Munich, Bavaria, Germany
🇩🇪
Klinikum Bogenhausen, Munich, Germany

and more 2 locations